European Regulators Reject Roche and Sarepta’s Gene Therapy, Raising Questions on Future of Muscular Dystrophy Treatments
Roche and Sarepta’s gene therapy Elevidys has been rejected by EU regulators, marking a significant setback for the companies and highlighting ongoing challenges in developing treatments for Duchenne muscular dystrophy.